<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272647</url>
  </required_header>
  <id_info>
    <org_study_id>14-002829</org_study_id>
    <nct_id>NCT02272647</nct_id>
  </id_info>
  <brief_title>Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women</brief_title>
  <official_title>Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Progesterone amplifies estrogen-stimulated Growth Hormone (GH) secretion in postmenopausal&#xD;
      women. Preliminary data are sought to estimate statistical power for more detailed studies of&#xD;
      this hypothesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The systemic availability and orderly secretion patterns of GH and sex steroids decline in&#xD;
      healthy aging men and women. The combined changes have substantial clinical implications to&#xD;
      aging-related physical frailty, diminished aerobic capacity, sarcopenia, osteopenia, visceral&#xD;
      adiposity, glucose intolerance, and reduced psychosocial wellbeing. Whereas androgen is&#xD;
      considered the main trophic (anabolic) sex steroid, recent data demonstrate that certain&#xD;
      tissues respond principally to GH and testosterone-derived estradiol, Estrogen (E2) (e.g.&#xD;
      bone, brain, liver and pituitary). In principle, frailty may thus be associated with dual GH&#xD;
      and sex-steroid deficiencies. Additionally, young, but not older healthy women secrete&#xD;
      significant amounts of progesterone for approximately 14 days during the luteal phase of&#xD;
      every menstrual cycle. When GH levels rise nearly two fold, the investigators hypothesize&#xD;
      that progesterone potentiates the GH response to E2. This hypothesis arises from scattered&#xD;
      indirect studies often using synthetic progestins with partial androgen agonism, instead of&#xD;
      progesterone per se.&#xD;
&#xD;
      Because there is no basis for estimating statistical power for this novel paradigm, 40 women,&#xD;
      10 each in 4 groups, will be studied. The pilot data will be used to calculate statistical&#xD;
      power for a definitive R01-based investigation of gender-specific distinctions in&#xD;
      estrogen-regulated pituitary-hormone secretion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Logarithm of the ratio of the normalized growth hormone secretion rate over the first 10 hr.</measure>
    <time_frame>The subject will be followed on average for a month. Growth hormone measurements will occur on Day 23 after initiation of study drug administration</time_frame>
    <description>Subjects will be given IM placebo/estradiol on Day 1. 10 days later they will receive IM placebo/estradiol again, then start progesterone/placebo capsules for 14 days. On Day 23, subjects will undergo a 12-h overnight (2200 - 1000h) fasting, 10-min blood sampling. The primary comparison parameter is the logarithm of the ratio of the normalized growth hormone secretion rate over the first 10 hr.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth hormone secretion post ghrelin injection</measure>
    <time_frame>The subject will be followed on average for a month. Growth hormone measurements will occur on Day 23 after initiation of study drug administration</time_frame>
    <description>Subjects will be given IM placebo/estradiol on Day 1. 10 days later they will receive IM placebo/estradiol again, then start progesterone/placebo capsules for 14 days. On Day 23, subjects will undergo a 12-h overnight (2200 - 1000h) fasting, 10-min blood sampling. A secondary outcome is GH secretion over the 2 hr after bolus ghrelin injection, a potent growth hormone secretagogue</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>IM Plac - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM Plac - Oral Prog - Ghrelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM E2 - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Medroxyprogesterone (5 mg - for 10 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM E2 - Oral Prog - Ghrelin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IM Saline Placebo (0.25 ml)</intervention_name>
    <arm_group_label>IM Plac - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM Plac - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IM Estradiol valerate (2.5 mg)</intervention_name>
    <arm_group_label>IM E2 - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM E2 - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IM Saline Placebo (0.5 ml)</intervention_name>
    <arm_group_label>IM Plac - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM Plac - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IM Estradiol valerate (5.0 mg)</intervention_name>
    <arm_group_label>IM E2 - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM E2 - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Micronized Progesterone</intervention_name>
    <arm_group_label>IM E2 - Oral Prog - Ghrelin</arm_group_label>
    <arm_group_label>IM Plac - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Placebo</intervention_name>
    <arm_group_label>IM E2 - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM Plac - Oral Plac - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ghrelin (0.3 ug/kg)</intervention_name>
    <arm_group_label>IM E2 - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM E2 - Oral Prog - Ghrelin</arm_group_label>
    <arm_group_label>IM Plac - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM Plac - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medroxyprogesterone - Acetate</intervention_name>
    <arm_group_label>IM E2 - Oral Plac - Ghrelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Placebo</intervention_name>
    <description>(in lieu of Medroxyprogesterone)</description>
    <arm_group_label>IM E2 - Oral Prog - Ghrelin</arm_group_label>
    <arm_group_label>IM Plac - Oral Plac - Ghrelin</arm_group_label>
    <arm_group_label>IM Plac - Oral Prog - Ghrelin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women ages 50 to 80&#xD;
&#xD;
          -  postmenopausal as defined by: any combination of the following&#xD;
&#xD;
               -  Hormonally postmenopausal for 1 year&#xD;
&#xD;
               -  Lh greater than 15 IU/L, FSH greater than 30 IU/L&#xD;
&#xD;
               -  Total hysterectomy with oophorectomy greater than one year&#xD;
&#xD;
               -  Hysterectomy with ovaries preserved with hormone levels: Lh &gt; 15 IU/L, FSH &gt; 30&#xD;
                  IU/L&#xD;
&#xD;
          -  Following laboratory results with normal range, unless PI approves out of range&#xD;
             values.&#xD;
&#xD;
          -  BMI 18 to 35&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  structural hypothalamo-pituitary-gonadal disease&#xD;
&#xD;
          -  endocrinopathy (diseases involving the following organs pituitary, thyroid, adrenals,&#xD;
             ovaries, testes and pancreas), other than primary thyroid failure receiving&#xD;
             replacement&#xD;
&#xD;
          -  recent (within 2 weeks) estrogen, progestin, anabolic steroid or glucocorticoid use&#xD;
&#xD;
          -  clinically significant ECG abnormality as determined by study team physicians&#xD;
&#xD;
          -  obstructive uropathy&#xD;
&#xD;
          -  history of a stroke&#xD;
&#xD;
          -  history of MI or angina&#xD;
&#xD;
          -  acute or chronic systemic disease&#xD;
&#xD;
          -  recent transmeridian travel (traversing more than 3 time zones within 7 days of&#xD;
             admission)&#xD;
&#xD;
          -  current night shift work&#xD;
&#xD;
          -  concurrent use of neuropsychiatric medications&#xD;
&#xD;
          -  alcohol or drug abuse, current and within 2 years&#xD;
&#xD;
          -  history of depression, psychosis, or mania&#xD;
&#xD;
          -  weight gain or loss (2 kg or more in 3 weeks)&#xD;
&#xD;
          -  BMI &gt; 35 kg/m2&#xD;
&#xD;
          -  anemia, hemoglobin less than 12.5 g/dl&#xD;
&#xD;
          -  abnormal hepatorenal function, creatinine outside normal range, ALT greater than two&#xD;
             times normal range&#xD;
&#xD;
          -  biochemical and chemistry lab results out of physician acceptable range&#xD;
&#xD;
          -  history of deep-vein thrombophlebitis&#xD;
&#xD;
          -  history of Congestive Heart Failure, cardiac arrhythmias, and medications used to&#xD;
             treat cardiac arrhythmias&#xD;
&#xD;
          -  known allergy to estradiol valerate, castor oil or sesame oil&#xD;
&#xD;
          -  history of smoking within the last 2 years&#xD;
&#xD;
          -  untreated gall bladder disease&#xD;
&#xD;
          -  lack of voluntary, written informed consent&#xD;
&#xD;
          -  history of carcinoma excluding localized basal cell or squamous cell, including women&#xD;
             with known, suspected or history of breast cancer&#xD;
&#xD;
          -  not clinically postmenopausal&#xD;
&#xD;
          -  women with allergies to nuts will not be enrolled in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>October 21, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Johannes D. Veldhuis</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Normal Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

